566 related articles for article (PubMed ID: 34803999)
1. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
3. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
De Bondt M; Renders J; Struyf S; Hellings N
Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
[TBL] [Abstract][Full Text] [Related]
6. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
Neys SFH; Rip J; Hendriks RW; Corneth OBJ
Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
[TBL] [Abstract][Full Text] [Related]
7. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
[TBL] [Abstract][Full Text] [Related]
8. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
Lin P; Zhang D; Lin J
Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
[TBL] [Abstract][Full Text] [Related]
9. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
10. Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Tichenor MS; Wiener JJM; Rao NL; Bacani GM; Wei J; Pooley Deckhut C; Barbay JK; Kreutter KD; Chang L; Clancy KW; Murrey HE; Wang W; Ahn K; Huber M; Rex E; Coe KJ; Wu J; Rui H; Sepassi K; Gaudiano M; Bekkers M; Cornelissen I; Packman K; Seierstad M; Xiouras C; Bembenek SD; Alexander R; Milligan C; Balasubramanian S; Lebsack AD; Venable JD; Philippar U; Edwards JP; Hirst G
J Med Chem; 2022 Nov; 65(21):14326-14336. PubMed ID: 36314537
[TBL] [Abstract][Full Text] [Related]
11. A Fast and Clean BTK Inhibitor.
Gabizon R; London N
J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases.
Zhang D; Gong H; Meng F
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443496
[TBL] [Abstract][Full Text] [Related]
13. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT
J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
15. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
Watterson SH; Liu Q; Beaudoin Bertrand M; Batt DG; Li L; Pattoli MA; Skala S; Cheng L; Obermeier MT; Moore R; Yang Z; Vickery R; Elzinga PA; Discenza L; D'Arienzo C; Gillooly KM; Taylor TL; Pulicicchio C; Zhang Y; Heimrich E; McIntyre KW; Ruan Q; Westhouse RA; Catlett IM; Zheng N; Chaudhry C; Dai J; Galella MA; Tebben AJ; Pokross M; Li J; Zhao R; Smith D; Rampulla R; Allentoff A; Wallace MA; Mathur A; Salter-Cid L; Macor JE; Carter PH; Fura A; Burke JR; Tino JA
J Med Chem; 2019 Apr; 62(7):3228-3250. PubMed ID: 30893553
[TBL] [Abstract][Full Text] [Related]
18. Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2016 Aug; 25(8):891-9. PubMed ID: 27148767
[TBL] [Abstract][Full Text] [Related]
19. BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria.
Bernstein JA; Maurer M; Saini SS
J Allergy Clin Immunol; 2024 May; 153(5):1229-1240. PubMed ID: 38141832
[TBL] [Abstract][Full Text] [Related]
20. The Development of BTK Inhibitors: A Five-Year Update.
Tasso B; Spallarossa A; Russo E; Brullo C
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
